Literature DB >> 21233968

Prognosis of common cancers.

P H Geggie.   

Abstract

Four cancers in each sex account for nearly 60% of all cases. Lung cancer therapy is stymied by a lack of effective agents, but can be prevented by a smoking cessation program. Breast cancer is far too prevalent, but has the best response rate to drugs and the best palliation of any of these tumours. Prostate cancer, once androgen deprivation has failed, is untreatable. Colorectal cancer therapy after years of inactivity is now exciting, while pancreas cancer remains almost untreatable. All Canadian patients should be encouraged to participate in clinical trials when appropriate.

Entities:  

Year:  1990        PMID: 21233968      PMCID: PMC2280477     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  24 in total

1.  Morbidity and mortality of local failure after definitive therapy for prostate cancer.

Authors:  P F Schellhammer; R B Whitmore; D A Kuban; A M el-Mahdi; L A Ladaga
Journal:  J Urol       Date:  1989-03       Impact factor: 7.450

Review 2.  Systemic adjuvant therapy for node-negative breast cancer.

Authors:  A D Ginsburg; D J Perrault; K I Pritchard; G P Browman; P B McCulloch; J Skillings
Journal:  CMAJ       Date:  1989-09-01       Impact factor: 8.262

Review 3.  Selecting patients with lung cancer for surgical therapy.

Authors:  M R Johnston
Journal:  Semin Oncol       Date:  1988-06       Impact factor: 4.929

Review 4.  Therapy of small cell lung cancer: a perspective on two decades of clinical research.

Authors:  E J Seifter; D C Ihde
Journal:  Semin Oncol       Date:  1988-06       Impact factor: 4.929

5.  Breast cancer therapy: exercising all our options.

Authors:  V T De Vita
Journal:  N Engl J Med       Date:  1989-02-23       Impact factor: 91.245

6.  Adjuvant therapy of node-negative breast cancer.

Authors:  W L McGuire
Journal:  N Engl J Med       Date:  1989-02-23       Impact factor: 91.245

7.  Prognosis and survival in resected lung carcinoma based on the new international staging system.

Authors:  T Naruke; T Goya; R Tsuchiya; K Suemasu
Journal:  J Thorac Cardiovasc Surg       Date:  1988-09       Impact factor: 5.209

8.  Factors influencing mortality after curative resection for large bowel cancer in elderly patients.

Authors:  L P Fielding; R K Phillips; R Hittinger
Journal:  Lancet       Date:  1989-03-18       Impact factor: 79.321

9.  A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors.

Authors:  B Fisher; C Redmond; N V Dimitrov; D Bowman; S Legault-Poisson; D L Wickerham; N Wolmark; E R Fisher; R Margolese; C Sutherland
Journal:  N Engl J Med       Date:  1989-02-23       Impact factor: 91.245

10.  Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer.

Authors:  S Ishikawa; M S Soloway; R Van der Zwaag; B Todd
Journal:  J Urol       Date:  1989-05       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.